

THIS PROSPECTUS HAS NOT BEEN REGISTERED BY THE SECURITIES COMMISSION MALAYSIA. THE INFORMATION IN THIS PROSPECTUS MAY BE SUBJECT TO FURTHER AMENDMENTS BEFORE BEING REGISTERED BY THE SECURITIES COMMISSION MALAYSIA. UNDER NO CIRCUMSTANCES SHALL THIS PROSPECTUS CONSTITUTE AN OFFER FOR SUBSCRIPTION OR PURCHASE OF, OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE SECURITIES.

PROSPECTUS



LAC MED BERHAD

(Registration No. 202401049485 (1595329-H))
(Incorporated in Malaysia under the Companies Act 2016)

INITIAL PUBLIC OFFERING (“IPO”) OF UP TO 124,197,600 ORDINARY SHARES IN LAC MED BERHAD (“LAC”) (“SHARES”) IN CONJUNCTION WITH THE LISTING OF AND QUOTATION FOR THE ENTIRE ENLARGED ISSUED SHARE CAPITAL OF LAC ON THE MAIN MARKET OF BURSA MALAYSIA SECURITIES BERHAD COMPRISING:

(I) PUBLIC ISSUE OF 74,197,600 NEW SHARES (“ISSUE SHARES”) IN THE FOLLOWING MANNER:

- 20,000,000 ISSUE SHARES FOR APPLICATION BY THE MALAYSIAN PUBLIC;
- 4,197,600 ISSUE SHARES FOR APPLICATION BY THE ELIGIBLE DIRECTORS, EMPLOYEES AND PERSONS WHO HAVE CONTRIBUTED TO THE SUCCESS OF LAC AND ITS SUBSIDIARIES; AND
- 50,000,000 ISSUE SHARES BY WAY OF PRIVATE PLACEMENT TO BUMIPUTERA INVESTORS APPROVED BY THE MINISTRY OF INVESTMENT, TRADE AND INDUSTRY OF MALAYSIA; AND

(II) OFFER FOR SALE OF UP TO 50,000,000 EXISTING SHARES (“OFFER SHARES”) BY WAY OF PRIVATE PLACEMENT TO INSTITUTIONAL AND SELECTED INVESTORS

SUBJECT TO THE CLAWBACK AND REALLOCATION PROVISIONS AS SET OUT IN THIS PROSPECTUS, AT AN ISSUE/OFFER PRICE OF RM[•] PER ISSUE/OFFER SHARE, PAYABLE IN FULL UPON APPLICATION

Principal Adviser, Sole Underwriter and Sole Placement Agent



RHB INVESTMENT BANK BERHAD

(Registration No. 197401002639 (19663-P))
(A Participating Organisation of Bursa Malaysia Securities Berhad)

NO SECURITIES WILL BE ALLOTTED OR ISSUED BASED ON THIS PROSPECTUS AFTER 6 MONTHS FROM THE DATE OF THIS PROSPECTUS.

[THE SECURITIES COMMISSION MALAYSIA (“SC”) HAS APPROVED THE ISSUE, OFFER OR INVITATION OF OUR IPO AND THIS PROSPECTUS HAS BEEN REGISTERED BY THE SC.] THE SAID APPROVAL AND REGISTRATION OF THIS PROSPECTUS, SHOULD NOT BE TAKEN TO INDICATE THAT THE SC RECOMMENDS THE OFFERING OR ASSUMES RESPONSIBILITY FOR THE CORRECTNESS OF ANY STATEMENT MADE, OPINION EXPRESSED OR REPORT CONTAINED IN THIS PROSPECTUS. THE SC HAS NOT, IN ANY WAY, CONSIDERED THE MERITS OF THE SECURITIES BEING OFFERED FOR INVESTMENT.

THE SC IS NOT LIABLE FOR ANY NON-DISCLOSURE ON THE PART OF OUR COMPANY AND TAKES NO RESPONSIBILITY FOR THE CONTENTS OF THIS PROSPECTUS, MAKES NO REPRESENTATION AS TO ITS ACCURACY OR COMPLETENESS, AND EXPRESSLY DISCLAIMS ANY LIABILITY FOR ANY LOSS YOU MAY SUFFER ARISING FROM OR IN RELIANCE UPON THE WHOLE OR ANY PART OF THE CONTENTS OF THIS PROSPECTUS.

INVESTORS ARE ADVISED TO READ AND UNDERSTAND THE CONTENTS OF THIS PROSPECTUS. IF IN DOUBT, PLEASE CONSULT A PROFESSIONAL ADVISER.

FOR INFORMATION CONCERNING RISK FACTORS WHICH SHOULD BE CONSIDERED BY PROSPECTIVE INVESTORS, SEE “RISK FACTORS” COMMENCING ON PAGE 178.

THIS PROSPECTUS IS DATED [•]

All defined terms used in this Prospectus are defined under “Presentation of Information” on page viii, “Definitions” on page x and “Glossary of Technical Terms” on page xvi.

RESPONSIBILITY STATEMENTS

Our Directors, Promoter and Offerors have seen and approved this Prospectus. They collectively and individually accept full responsibility for the accuracy of the information contained in this Prospectus. Having made all reasonable enquiries, and to the best of their knowledge and belief, they confirm that there is no false or misleading statement or other facts which, if omitted, would make any statement in this Prospectus false or misleading.

RHB Investment Bank, being our Principal Adviser, acknowledges that, based on all available information, and to the best of its knowledge and belief, this Prospectus constitutes a full and true disclosure of all material facts concerning our IPO.

STATEMENTS OF DISCLAIMER

Our Company [has obtained] the approval from Bursa Securities for the listing of and quotation for our Shares. Our admission to the Official List of Bursa Securities is not to be taken as an indication of the merits of our IPO, our Company or our Shares.

This Prospectus, together with the Application Form, [has also been lodged] with the Registrar of Companies, who takes no responsibility for its contents.

You should rely on your own evaluation to assess the merits and risks of your investment in our Shares. If you are in any doubt as to the action to be taken, you should consult your stockbroker, bank manager, solicitor, accountant or other professional advisers immediately.

You should not take the agreement by the Sole Underwriter named in this Prospectus to underwrite our IPO Shares as an indication of the merits of our Shares being offered.

OTHER STATEMENTS

You should note that you may seek recourse under Sections 248, 249 and 357 of the CMSA for breaches of securities laws including any statement in this Prospectus that is false, misleading, or from which there is a material omission, or for any misleading or deceptive act in relation to this Prospectus or the conduct of any other person in relation to our Company.

Our Shares are offered to the public on the premise of full and accurate disclosure of all material information concerning our IPO, for which any person set out in Section 236 of the CMSA, is responsible.

This Prospectus is prepared and published solely for our IPO. Our Shares being offered in our IPO are offered solely on the basis of the information contained and representations made in this Prospectus. Our Company, Directors, Promoter, Offerors, Principal Adviser, Sole Underwriter and Sole Placement Agent have not authorised anyone to provide any information or to make any representation not contained in this Prospectus. Any information or representation not contained in this Prospectus must not be relied upon as having been authorised by our Company, Directors, Promoter, Offerors, Principal Adviser, Sole Underwriter and Sole Placement Agent, or any of their respective directors or any other persons involved in our IPO.

This Prospectus has been prepared and published in the context of an IPO under the laws of Malaysia. It does not comply with the laws of any jurisdiction other than Malaysia, and has not been and will not be lodged, registered or approved pursuant to or under any applicable securities or equivalent legislation or by any regulatory authority of any jurisdiction other than Malaysia.

The distribution of this Prospectus and our IPO are subject to the laws of Malaysia. This Prospectus will not be distributed outside Malaysia. Our Company, Directors, Promoter, Offerors, Principal Adviser, Sole Underwriter and Sole Placement Agent have not authorised and take no responsibility for the distribution of this Prospectus outside Malaysia. No action has been taken to permit a public offering of our Shares in any jurisdiction other than Malaysia based on this Prospectus. Accordingly, this Prospectus may not be used for the purpose of, and does not constitute an offer for, subscription or purchase or invitation to subscribe for or purchase any of our Shares being offered in our IPO in any jurisdiction or in any circumstance in which such an offer is not authorised or lawful, or to any person to whom it is unlawful to make such offer or invitation. The distribution of this Prospectus and the sale of our Shares offered under our IPO in certain jurisdictions may be restricted by law. Prospective investors who may be in possession of this Prospectus are required to inform themselves and to observe such restrictions.

We will not, prior to acting on any acceptance in respect of our IPO, make or be bound to make any enquiry as to whether you have a registered address in Malaysia and will not be deemed to accept any liability in relation thereto, whether or not any enquiry or investigation is made in connection therewith.

It is your sole responsibility to ensure that your application for our IPO would be in compliance with the terms of our IPO as stated in this Prospectus and would not be in contravention of any laws of countries or jurisdictions other than Malaysia to which you may be subjected. We will further assume that you had accepted our IPO in Malaysia and will be subjected only to the laws of Malaysia in connection therewith. However, we reserve the right in our absolute discretion to treat any acceptance as invalid if we believe that such acceptance may violate any law or applicable legal or regulatory requirements.

It shall be your sole responsibility to consult your legal and/or other professional advisers on the laws to which our IPO or you are or might be subjected. Neither we nor our Principal Adviser, Sole Underwriter and Sole Placement Agent nor any other advisers in relation to our IPO shall accept any responsibility or liability in the event that any application made by you shall become illegal, unenforceable, avoidable or void in any country or jurisdiction.

ELECTRONIC PROSPECTUS

This Prospectus can also be viewed or downloaded from Bursa Securities' website at www.bursamalaysia.com. The contents of the electronic Prospectus and the copy of this Prospectus registered with the SC are the same.

You are advised that the internet is not a fully secure medium. Your Internet Share Application may be subject to risks in data transmission, computer security threats such as viruses, hackers and crackers, faults with computer software and other events beyond the control of the Internet Participating Financial Institutions. These risks cannot be borne by the Internet Participating Financial Institutions. If you are in any doubt about the validity or integrity of the electronic Prospectus, you should immediately request from us or our Issuing House, a paper/printed copy of this Prospectus. If there are any discrepancies between the contents of the electronic Prospectus and the paper/printed copy of this Prospectus, the contents of the paper/printed copy of this Prospectus, which are identical to the copy of this Prospectus registered with the SC, shall prevail.

In relation to any reference in this Prospectus to third party internet sites ("**Third Party Internet Sites**"), whether by way of hyperlinks or by way of description of the Third Party Internet Sites, you acknowledge and agree that:

- (i) we do not endorse and are not affiliated in any way with the Third Party Internet Sites. Accordingly, we are not responsible for the availability of, or the contents or any data, information, file or other material provided on the Third Party Internet Sites. You shall bear all risks associated with the access to or use of the Third Party Internet Sites;

- (ii) we are not responsible for the quality of products or services in the Third Party Internet Sites, particularly in fulfilling any of the terms of your agreements with the Third Party Internet Sites. We are also not responsible for any loss or damage or costs that you may suffer or incur in connection with or as a result of dealing with the Third Party Internet Sites or the use of or reliance on any data, information, file or other material provided by the Third Party Internet Sites; and
- (iii) any data, information, file or other material downloaded from the Third Party Internet Sites is done at your own discretion and risk. We are not responsible, liable or under obligations for any damage to your computer system or loss of data resulting from the downloading of any such data, information, file or other material.

Where an electronic Prospectus is hosted on the website of the Internet Participating Financial Institutions, you are advised that:

- (i) the Internet Participating Financial Institutions are only liable in respect of the integrity of the contents of the electronic Prospectus, to the extent of the contents of the electronic Prospectus on the web server of the Internet Participating Financial Institutions which may be viewed via your web browser or other relevant software. The Internet Participating Financial Institutions are not responsible for the integrity of the contents of the electronic Prospectus which has been obtained from the web server of the Internet Participating Financial Institutions and subsequently communicated or disseminated in any manner to you or other parties;
- (ii) while all reasonable measures have been taken to ensure the accuracy and reliability of the information provided in the electronic Prospectus, the accuracy and reliability of the electronic Prospectus cannot be guaranteed because the internet is not a fully secure medium; and
- (iii) the Internet Participating Financial Institutions are not liable (whether in tort or contract or otherwise) for any loss, damages or costs, that you or any other person may suffer or incur due to, as a consequence of or in connection with any inaccuracies, changes, alterations, deletions or omissions in respect of the information provided in the electronic Prospectus which may arise in connection with or as a result of any fault with web browsers or other relevant software, any fault on your or any third party's personal computer, operating system or other software, viruses or other security threats, unauthorised access to information or systems in relation to the website of the Internet Participating Financial Institutions, and/or problems occurring during data transmission, which may result in inaccurate or incomplete copies of information being downloaded or displayed on your personal computer.

INDICATIVE TIMETABLE

An indicative timetable for our IPO is set out below:

Event	Tentative date
Issuance of the Prospectus/Opening of application for our IPO Shares	10.00 a.m. [●]
Closing of application for our IPO Shares	5.00 p.m. [●]
Balloting of application for our IPO Shares	[●]
Allotment/Transfer of our IPO Shares to successful applicants	[●]
Listing	[●]

If there is any change to the timetable, we will advertise the notice of such change in a widely circulated English and Bahasa Malaysia daily newspapers in Malaysia, and make an announcement on the website of Bursa Securities.

TABLE OF CONTENTS

	PAGE
PRESENTATION OF INFORMATION	viii
FORWARD-LOOKING STATEMENTS	ix
DEFINITIONS	x
GLOSSARY OF TECHNICAL TERMS	xvi
1. CORPORATE DIRECTORY	1
2. PROSPECTUS SUMMARY	4
2.1 PRINCIPAL DETAILS OF OUR IPO	4
2.2 OUR BUSINESS	4
2.3 COMPETITIVE ADVANTAGES AND KEY STRENGTHS	6
2.4 STRATEGIES AND PLANS	7
2.5 RISK FACTORS	8
2.6 DIRECTORS AND KEY SENIOR MANAGEMENT	10
2.7 PROMOTER AND SUBSTANTIAL SHAREHOLDERS	10
2.8 USE OF PROCEEDS	11
2.9 FINANCIAL HIGHLIGHTS	12
2.10 DIVIDEND POLICY	13
3. APPROVALS AND CONDITIONS	14
3.1 APPROVALS AND CONDITIONS	14
3.2 MORATORIUM ON OUR SHARES	15
4. DETAILS OF OUR IPO	16
4.1 PARTICULARS OF OUR IPO	16
4.2 BASIS OF ARRIVING AT THE IPO PRICE	22
4.3 DILUTION	23
4.4 USE OF PROCEEDS	24
4.5 BROKERAGE FEE, UNDERWRITING COMMISSION AND PLACEMENT FEE	28
4.6 SALIENT TERMS OF THE UNDERWRITING AGREEMENT	29
5. INFORMATION ON OUR PROMOTER, SUBSTANTIAL SHAREHOLDERS, DIRECTORS AND KEY SENIOR MANAGEMENT	30
5.1 PROMOTER AND SUBSTANTIAL SHAREHOLDERS	30
5.2 DIRECTORS	35
5.3 BOARD PRACTICES	52
5.4 KEY SENIOR MANAGEMENT	55
5.5 FAMILY RELATIONSHIPS AND ASSOCIATIONS BETWEEN OUR PROMOTER, SUBSTANTIAL SHAREHOLDERS, DIRECTORS AND KEY SENIOR MANAGEMENT	64
5.6 DECLARATIONS BY OUR PROMOTER, DIRECTORS AND KEY SENIOR MANAGEMENT	64
5.7 SERVICE CONTRACTS	65
6. INFORMATION ON OUR GROUP	66
6.1 OUR GROUP	66
6.2 OUR GROUP STRUCTURE	68
6.3 BUSINESS HISTORY AND MILESTONES	69
6.4 AWARDS AND RECOGNITIONS	71
6.5 INFORMATION ON OUR SUBSIDIARIES	71
6.6 MATERIAL INVESTMENTS AND DIVESTITURES	75

TABLE OF CONTENTS (CONT'D)

	PAGE
7. BUSINESS OVERVIEW	76
7.1 OVERVIEW OF OUR BUSINESS	76
7.2 MODE OF OPERATION	83
7.3 COMPETITIVE ADVANTAGES AND KEY STRENGTHS	86
7.4 PRINCIPAL BUSINESS ACTIVITIES, PRODUCTS AND SERVICES	89
7.5 APPLICATION OF THE MEDICAL DEVICES WE SUPPLY	103
7.6 OUR AUTHORISED BRANDS	104
7.7 OPERATIONAL FACILITIES	106
7.8 MACHINERY AND EQUIPMENT	107
7.9 CAPACITY AND UTILISATION	107
7.10 PROCESS FLOW	108
7.11 RESEARCH AND DEVELOPMENT	112
7.12 TECHNOLOGIES USED	112
7.13 SEASONALITY	112
7.14 MATERIAL INTERRUPTIONS IN OUR BUSINESS	113
7.15 SALES AND MARKETING ACTIVITIES	113
7.16 TYPES AND SOURCES OF INPUT MATERIALS AND SERVICES	114
7.17 MAJOR CUSTOMERS	115
7.18 MAJOR SUPPLIERS	117
7.19 EMPLOYEES	120
7.20 OVERVIEW OF OUR STRATEGIES AND PLANS	120
7.21 MATERIAL DEPENDENCY ON CONTRACTS	127
7.22 INTELLECTUAL PROPERTY RIGHTS	131
7.23 MAJOR APPROVALS, LICENCES AND PERMITS	134
7.24 MATERIAL PROPERTIES	155
7.25 GOVERNING LAWS AND REGULATIONS	158
7.26 ENVIRONMENTAL, SOCIAL AND GOVERNANCE PRACTICES	164
8. INDUSTRY OVERVIEW	167
9. RISK FACTORS	178
9.1 RISKS RELATING TO OUR BUSINESS AND OPERATIONS	178
9.2 RISKS RELATING TO OUR INDUSTRY	183
9.3 RISKS RELATING TO INVESTMENT IN OUR SHARES	184
10. RELATED PARTY TRANSACTIONS	187
10.1 RELATED PARTY TRANSACTIONS	187
10.2 MONITORING AND OVERSIGHT OF RELATED PARTY TRANSACTIONS	191
11. CONFLICT OF INTEREST	192
11.1 INTEREST IN SIMILAR BUSINESS	192
11.2 DECLARATIONS BY ADVISERS ON CONFLICT OF INTEREST	194
12. FINANCIAL INFORMATION	196
12.1 HISTORICAL COMBINED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME AND FINANCIAL POSITION	196
12.2 CAPITALISATION AND INDEBTEDNESS	199
12.3 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	200
12.4 LIQUIDITY AND CAPITAL RESOURCES	216
12.5 ORDER BOOK	226
12.6 TREND INFORMATION	226
12.7 DIVIDEND POLICY	226
12.8 REPORTING ACCOUNTANTS' REPORT ON THE COMPILATION OF PRO FORMA COMBINED STATEMENTS OF FINANCIAL POSITION	228

TABLE OF CONTENTS (CONT'D)

	PAGE
13. ACCOUNTANTS' REPORT	245
14. ADDITIONAL INFORMATION	328
14.1 EXTRACTS OF OUR CONSTITUTION.....	328
14.2 LIMITATION ON THE RIGHTS TO OWN SECURITIES	331
14.3 DEPOSITED SECURITIES AND RIGHTS OF DEPOSITORS	331
14.4 SHARE CAPITAL.....	331
14.5 PUBLIC TAKE-OVERS.....	332
14.6 REPATRIATION OF CAPITAL, REMITTANCE OF PROFIT AND TAXATION.....	332
14.7 MATERIAL CONTRACTS.....	333
14.8 MATERIAL LITIGATION	334
14.9 CONSENTS	334
14.10 DOCUMENTS AVAILABLE FOR INSPECTION.....	334
14.11 RESPONSIBILITY STATEMENTS	335
15. SUMMARISED PROCEDURES FOR APPLICATION AND ACCEPTANCE	336
15.1 OPENING AND CLOSING OF APPLICATIONS	336
15.2 METHODS OF APPLICATION	336
15.3 ELIGIBILITY	337
15.4 APPLICATION BY WAY OF APPLICATION FORM.....	338
15.5 APPLICATION BY WAY OF ELECTRONIC SHARE APPLICATION	339
15.6 APPLICATION BY WAY OF INTERNET SHARE APPLICATION.....	339
15.7 AUTHORITY OF OUR BOARD AND THE ISSUING HOUSE.....	339
15.8 OVER / UNDERSUBSCRIPTION	340
15.9 UNSUCCESSFUL / PARTIALLY SUCCESSFUL APPLICANTS	340
15.10 SUCCESSFUL APPLICANTS	341
15.11 ENQUIRIES	342

PRESENTATION OF INFORMATION

All references to “our Company” or “LAC” in this Prospectus are to LAC Med Berhad. All references to “our Group” or “LAC Group” in this Prospectus are to our Company and our subsidiaries, taken as a whole. All references to “we”, “us”, “our” or “ourselves” are to our Company, and where the context requires, our Company and our subsidiaries.

All references to “you” are to our prospective investors.

Unless the context otherwise requires, references to “management” in this Prospectus are to our Directors and Key Senior Management as at the date of this Prospectus. Statements as to our beliefs, expectations, estimates and opinions are those of our management.

The word “approximately” used in this Prospectus is to indicate that a number is not an exact one, but that number is usually rounded off to the nearest thousandth or 1 decimal place. Any discrepancies in the tables between the amounts listed and the totals in this Prospectus are due to rounding. Certain acronyms, technical terms and other abbreviations used are defined in “Definitions” and “Glossary of Technical Terms” sections of this Prospectus.

Words denoting the singular shall, where applicable, include the plural and vice versa and words denoting the masculine gender shall, where applicable, include the feminine and/or neuter genders and vice versa. References to persons shall include companies and corporations.

Any reference in this Prospectus to any provisions of the statutes, rules and regulations, enactments or rules of stock exchange shall (where the context admits), be construed as reference to provisions of such statutes, rules and regulations, enactments or rules of stock exchange (as the case may be) as modified by any written law or (if applicable) amendment or re-enactment to statutes, rules and regulations, enactments or rules of stock exchange for the time being in force.

All reference to dates and times are references to dates and times in Malaysia unless otherwise stated. All references to the “LPD” in this Prospectus are to 2 May 2025, which is the latest practicable date prior to the registration of this Prospectus with the SC.

This Prospectus includes statistical data provided by us and various third parties and cites third party projections regarding growth and performance of the market and industry in which we operate as well as our estimated market share in the industry in which we operate. This data is taken or derived from information published by industry sources and from our internal data. In each such case, the source is stated in this Prospectus. Where there is no source stated, it can be assumed that the information originates from us or is extracted from the IMR Report prepared by Vital Factor Consulting Sdn Bhd, which is included in Section 8 of this Prospectus. We have appointed Vital Factor Consulting Sdn Bhd to provide an independent market and industry review. In compiling its data for the review, Vital Factor Consulting Sdn Bhd had relied on its research methodology, industry sources, published materials, its own private databases and direct contacts within the industry.

We believe that the information on the industry as contained in this Prospectus and other statistical data and projections cited in this Prospectus are useful in helping you to understand the major trends in the market and industry in which we operate. Third party projections cited in this Prospectus are subject to significant uncertainties that could cause actual data to differ materially from the projected figures. No assurance can be given that the estimated figures will be achieved, and you should not place undue reliance on the third party projections cited in this Prospectus.

The information on our website or any website, directly or indirectly, linked to our website does not form part of this Prospectus. If there is any discrepancy between the contents of such website relating to our Group and this Prospectus, the information contained in this Prospectus shall prevail.

FORWARD-LOOKING STATEMENTS

This Prospectus contains forward-looking statements. All statements other than statements of historical facts included in this Prospectus, including, without limitation, those regarding our financial position, business strategies, prospects, plans and objectives of our Group for future operations, are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, our performance or achievements, or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such forward-looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. Such forward-looking statements reflect our current views with respect to future events and do not guarantee future performance.

Forward-looking statements can be identified by the use of forward-looking terminologies such as the words “may”, “will”, “would”, “could”, “believe”, “expect”, “anticipate”, “intend”, “estimate”, “aim”, “plan”, “forecast”, “project” or similar expressions and include all statements that are not historical facts. Such forward-looking statements include, without limitation, statements relating to:

- (i) our plans and objectives for future operations;
- (ii) our future earnings, cash flow and liquidity;
- (iii) potential growth opportunities;
- (iv) our business strategies, trends and competitive position;
- (v) our financial position;
- (vi) our ability to pay dividends; and
- (vii) the regulatory environment and the effects of future regulation.

Our actual results may differ materially from information contained in such forward-looking statements as a result of a number of factors, including, without limitations, those discussed in Section 9 of this Prospectus on “Risk Factors” and Section 12.3 of this Prospectus on “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. We cannot give any assurance that the forward-looking statements made in this Prospectus will be realised. Such forward-looking statements are made only as at the LPD based on information available to us as at the LPD.

Should we become aware of any subsequent significant change or development affecting matters disclosed in this Prospectus arising from the date of registration of this Prospectus but before the date of allotment/transfer of our IPO Shares, we will issue a supplemental or replacement prospectus, as the case may be, in accordance with the provisions of Section 238(1) of the CMA and Paragraph 1.02, Chapter 1 of Part II (Division 6) of the Prospectus Guidelines (Supplementary and Replacement Prospectus).

DEFINITIONS

The following terms in this Prospectus bear the same meanings as set out below unless the term is defined otherwise or the context requires otherwise:

ACCA	: Association of Chartered Certified Accountants
Acquisitions	: Acquisition by LAC of the entire equity interest in LAC Medical, CVS Medical and GoCloud for a total purchase consideration of RM48,870,357, which was satisfied via the issuance of 325,802,380 new Shares at an issue price of RM0.15 per Share. The Acquisitions were completed on [●] 2025
Acquisitions SSAs	: Collectively, the following share sale agreements dated 9 April 2025: <ul style="list-style-type: none"> (i) share sale agreement entered into between LAC with Giam Teck Eng, Liew Yoon Kit, Liew Yoon Poh and Chan Yue Mun for the sale of the entire equity interest in LAC Medical for a total purchase consideration of RM34,383,117, to be satisfied via the issuance of 229,220,780 new Shares at an issue price of RM0.15 per Share; (ii) share sale agreement entered into between LAC with Giam Teck Eng, Liew Yoon Kit, Liew Yoon Poh and Chan Yue Mun for the sale of the entire equity interest in CVS Medical for a total purchase consideration of RM13,455,930, to be satisfied via the issuance of 89,706,200 new Shares at an issue price of RM0.15 per Share; and (iii) share sale agreement entered into between LAC with Hong Chong Chet and Noor Izwan Fazly Bin Nor Azman for the sale of the entire equity interest in GoCloud for a total purchase consideration of RM1,031,310, to be satisfied via the issuance of 6,875,400 new Shares at an issue price of RM0.15 per Share
Act	: Companies Act 2016
ADA	: Authorised Depository Agent, a person appointed by Bursa Depository under the Rules of Bursa Depository
AELB	: Atomic Energy Licencing Board
AGM	: Annual general meeting
Application	: Application for our IPO Shares under the Retail Offering by way of the Application Form, Electronic Share Application or Internet Share Application
Application Form	: Application form for the application of our IPO Shares under the Retail Offering accompanying this Prospectus
ATM	: Automated teller machine
Authorised Financial Institution	: Authorised financial institution participating in the Internet Share Application in respect of the payment for our IPO Shares
BNM	: Bank Negara Malaysia
Board	: Board of Directors of our Company
Bursa Depository	: Bursa Malaysia Depository Sdn Bhd
Bursa Securities	: Bursa Malaysia Securities Berhad

DEFINITIONS (CONT'D)

CCC or CF	: Certificate of completion and compliance or certificate of fitness for occupation
CDS	: Central Depository System
CIDB	: Construction Industry Development Board Malaysia
CIDB Act	: Lembaga Pembangunan Industri Pembinaan Malaysia Act 1994
CMSA	: Capital Markets and Services Act 2007
Constitution	: Constitution of our Company
Customer A	: Customer A is a private limited company incorporated in Malaysia and is a concessionaire principally involved in the provision of support services to public hospitals in Malaysia. It is a subsidiary of an asset management and infrastructure solutions company listed on Bursa Securities. We supply and integrate medical devices, as well as provide maintenance services to Customer A. The identity of Customer A is not disclosed as consent for such disclosure in the Prospectus was declined
Customer B	: Customer B and its subsidiaries are principally involved in the provision of healthcare services in Malaysia. We supply and integrate medical devices for Customer B. The identity of Customer B is not disclosed as consent for such disclosure in the Prospectus was declined
Customer C	: Customer C and its subsidiaries are principally involved in the operation of specialist hospitals in Malaysia. Customer C is listed on Bursa Securities. We supply and integrate medical devices, as well as provide maintenance services to Customer C. The identity of Customer C is not disclosed as consent for such disclosure in the Prospectus was declined
CVS Medical	: CVS Medical Sdn Bhd, our wholly-owned subsidiary
Director	: Director of our Company and within the meaning given in Section 2 of the Act
DLP	: Defect liability period
DOSH	: Department of Occupational Safety and Health
DPMD	: Distribution Practice for Medical Devices
EaaS	: Equipment-as-a-Service
EBITDA	: Earnings before interest, taxation, depreciation and amortisation
Electronic Share Application	: Application for our IPO Shares made available to the Malaysian Public under the Retail Offering through a Participating Financial Institution's ATM
Eligible Persons	: Collectively, eligible directors and employees of our Group and persons who have contributed to the success of our Group
EPS	: Earnings per Share
EUR	: Euro, the lawful currency of the European Union
Financial Years Under Review	: Collectively, the FYE 2022, FYE 2023 and FYE 2024

DEFINITIONS (CONT'D)

FYE	: Financial year ended/ending 31 December, as the case may be
Glocomp	: Glocomp Systems (M) Sdn Bhd
GoCloud	: GoCloud Solutions Sdn Bhd, our wholly-owned subsidiary
GP	: Gross profit
ICDM	: Institute of Corporate Directors Malaysia
ICT	: Information and communication technology
IDR	: Indonesian Rupiah, the lawful currency of Indonesia
IHH Healthcare Group	: Collectively, IHH Healthcare Berhad and its subsidiaries
IMR Report	: Independent market research report on the Independent Assessment of the Distribution of the Medical Device Industry in Malaysia prepared by Vital Factor Consulting Sdn Bhd as set out in Section 8 of this Prospectus
Institutional Offering	: Offering of up to 100,000,000 IPO Shares at the IPO Price, subject to the clawback and reallocation provisions, to institutional and selected investors as well as Bumiputera investors approved by the MITI
Internet Participating Financial Institutions	: Participating financial institutions for the Internet Share Application, which are set out in Section 15.6 of this Prospectus
Internet Share Application	: Application for our IPO Shares under the Retail Offering through an Internet Participating Financial Institution
IPO	: Initial public offering comprising the Public Issue and Offer for Sale
IPO Price	: Issue/offer price of RM[●] per IPO Share pursuant to our IPO
IPO Shares	: Collectively, the Issue Shares and Offer Shares
IRB	: Inland Revenue Board of Malaysia
Issue Shares	: 74,197,600 new Shares to be issued by our Company pursuant to the Public Issue
Issuing House	: AscendServ Capital Markets Services Sdn Bhd
Key Senior Management	: Key senior management of our Group, namely Hong Chong Chet, Thean Yain Peng, Teh Peng Ting, Sum Sheau San and Choo Mei Peng
LAC or Company	: LAC Med Berhad
LAC Group or Group	: Collectively, LAC and our subsidiaries
LAC Medical	: LAC Medical Supplies Sdn Bhd, our wholly-owned subsidiary
LAD	: Liquidated ascertained damages
Listing	: Listing of and quotation for the entire enlarged issued share capital of LAC on the Main Market of Bursa Securities
Listing Requirements	: Main Market Listing Requirements of Bursa Securities

DEFINITIONS (CONT'D)

LPD	: 2 May 2025, being the latest practicable date prior to the registration of this Prospectus with the SC
M&E	: Mechanical and electrical
Malaysian Public	: Malaysian citizens, companies, societies, co-operatives and institutions incorporated or organised under the laws of Malaysia
Market Day	: A day on which Bursa Securities is open for trading in securities
MCCG	: Malaysian Code on Corporate Governance
MDA	: Medical Device Authority
MDA 2012	: Medical Device Act 2012
MEAMS	: Medical device asset management services
MIA	: Malaysian Institute of Accountants
MITI	: Ministry of Investment, Trade and Industry of Malaysia
MOH	: Ministry of Health Malaysia
MRI	: Magnetic resonance imaging
MyIPO	: Intellectual Property Corporation of Malaysia
NA	: Net assets
Offer for Sale	: Offer for sale of the Offer Shares by our Offerors at the IPO Price
Offer Shares	: Up to 50,000,000 existing Shares to be offered pursuant to the Offer for Sale
Offerors	: Collectively, Liew Yoon Poh, Liew Yoon Kit and Giam Teck Eng
Official List	: A list specifying all securities listed on Bursa Securities
Participating Financial Institutions	: Participating financial institutions for the Electronic Share Application, which are set out in Section 15.5 of this Prospectus
PAT	: Profit after taxation
PBT	: Profit before taxation
Philips	: Collectively, Philips Malaysia and its related corporations
Philips Malaysia	: Philips Malaysia Sdn Bhd
Pink Form Allocations	: Allocation of 4,197,600 Issue Shares to the Eligible Persons
Promoter	: Liew Yoon Poh
Prospectus	: This prospectus dated [●] in relation to our IPO
Prospectus Guidelines	: Prospectus Guidelines issued by the SC
PT Fairmed	: PT Fairmed Imaging Nusajaya, our 95%-owned subsidiary

DEFINITIONS (CONT'D)

Public Issue	: Public issue of the Issue Shares at the IPO Price
Retail Offering	: Offering of 24,197,600 Issue Shares at the IPO Price, subject to the clawback and reallocation provisions, to the Malaysian Public and Eligible Persons
RHB Investment Bank or Principal Adviser or Sole Underwriter or Sole Placement Agent	: RHB Investment Bank Berhad
RM and sen	: Ringgit Malaysia and sen respectively, the lawful currency of Malaysia
Rules of Bursa Depository	: Rules of Bursa Depository as issued under the SICDA
SaaS	: Software-as-a-Service
Samsung	: Collectively, Samsung Malaysia and its related corporations
Samsung Malaysia	: Samsung Malaysia Electronics (SME) Sdn Bhd
SC	: Securities Commission Malaysia
Share Registrar	: AscendServ Capital Markets Services Sdn Bhd
Share Transfers	: Collectively, the following share transfers which were completed on 8 April 2025: <ul style="list-style-type: none"> (i) share transfer by Giam Teck Eng of approximately 11.7% equity interest in both LAC Medical and CVS Medical to Chan Yue Mun for a cash consideration of RM2,689,755 and RM285,403 respectively; and (ii) share transfer by Liew Yoon Kit of approximately 11.7% equity interests in both LAC Medical and CVS Medical to Chan Yue Mun for a cash consideration of RM2,689,755 and RM285,403 respectively
Share Transfers SSAs	: Collectively, the following share sale agreements dated 24 January 2025: <ul style="list-style-type: none"> (i) share sale agreement entered into between Giam Teck Eng and Chan Yue Mun for the sale of 116,667 ordinary shares or approximately 11.7% equity interest in LAC Medical for a cash consideration of RM2,689,755; (ii) share sale agreement entered into between Giam Teck Eng and Chan Yue Mun for the sale of 116,667 ordinary shares or approximately 11.7% equity interest in CVS Medical for a cash consideration of RM285,403; (iii) share sale agreement entered into between Liew Yoon Kit and Chan Yue Mun for the sale of 116,667 ordinary shares or approximately 11.7% equity interest in LAC Medical for a cash consideration of RM2,689,755; and (iv) share sale agreement entered into between Liew Yoon Kit and Chan Yue Mun for the sale of 116,667 ordinary shares or approximately 11.7% equity interest in CVS Medical for a cash consideration of RM285,403
Shares	: Ordinary shares in our Company
SICDA	: Securities Industry (Central Depositories) Act 1991

DEFINITIONS (CONT'D)

SKU	: Stock keeping unit
sq ft	: Square feet
Substantial Shareholders	: Collectively, Liew Yoon Poh, Liew Yoon Kit, Giam Teck Eng and Chan Yue Mun
Sunway Healthcare Group	: Collectively, Sunway Healthcare Holdings Sdn Bhd and its subsidiaries
Underwriting Agreement	: Underwriting agreement dated [●] entered into between our Company and our Sole Underwriter for the underwriting of 24,197,600 Issue Shares under the Retail Offering
USD	: United States Dollar, the lawful currency of United States

GLOSSARY OF TECHNICAL TERMS

The following technical terms in this Prospectus bear the same meanings as set out below unless the technical term is defined otherwise or the context requires otherwise:

Active medical devices/equipment	: Medical devices/equipment which require an external power source, such as electricity or batteries, to perform automated or powered tasks
Angiography system	: Medical equipment used for diagnosing and treating vascular conditions, such as angioplasty, to restore blood flow
Angioplasty	: Refers to the medical procedure to widen the blocked arteries and restore blood flow
Cardiovascular	: Refers to diseases or conditions that affect the heart and blood vessels
Computer tomography (CT) scanners	: A type of radiographic equipment which uses X-ray and computer processing to provide detailed and cross-sectional images of the body
Consumables	: Refers to single-use medical devices or disposable products such as catheters
Diagnostic	: Refers to the process of detecting or identifying medical conditions
Fixed equipment	: Medical equipment or machines which are permanently installed or attached to a structure, such as a wall, ceiling or floor in the healthcare facility, and the installation requires major M&E works
Fluoroscopy system	: A type of radiographic equipment which uses X-ray to produce dynamic and real-time X-ray images of the inside of the body
Imaging	: Refers to the techniques such as X-ray, ultrasound, and magnetic resonance used to create real-time or static images of the body's internal structures, tissues and fluids
Internet of Things (IoT)	: Refers to a network of devices embedded with sensors, software and network connectivity, which are able to collect and transfer data over the internet
Intravascular ultrasound (IVUS)	: A type of ultrasound machine with an ultrasound transducer at the tip of a catheter to emit sound waves, allowing real-time visualisation of the interior of blood vessels
Loose equipment	: "Plug and play" or loose/portable equipment that is easily connected to utility sources such as power and water
Magnetic resonance imaging (MRI) machine	: Medical equipment that uses strong magnetic fields and radio waves to create detailed images of the body's internal structures, tissues and fluids
Medical device	: Instrument, apparatus, implement, machine, appliance, implant, in vitro reagent, software, or material intended to be used, alone or in combination, for human beings for medical purposes
Medical equipment	: Generally refers to larger medical devices, machines or equipment that require power, maintenance or installation
Neurovascular device	: Refers to medical devices used for minimally invasive procedures for the treatment of neurovascular conditions such as stroke

GLOSSARY OF TECHNICAL TERMS (CONT'D)

Non-active (passive) medical devices	: Medical devices that can operate without external power, functioning mechanically or chemically through manual operation or body interaction
Obstetrics and gynaecology (O&G)	: A medical specialty focusing on the health of female reproductive system, pregnancy, childbirth as well as postpartum period
Radiographic equipment	: Medical equipment which uses X-ray technology to capture images of the body's internal structures and tissues
Radiographs	: Images captured or produced using X-ray to view the internal structures of the body
Therapeutic	: Refers to the treatment or interventions to cure medical conditions, as well as strategies to prevent potential health issues
Ultrasound machine	: Medical equipment which uses high-frequency sound waves to create real-time images of the internal structures and tissues of the body
X-ray	: A form of electromagnetic radiation